Basf Aktiengesellschaft

Abbott Laboratories Corporation

Knoll Aktiengesellschaft

Michael Kirchengast

Klaus M&uuml;nter

Wilfried Lubisch

Sabine Schult

Berthold Behl

Gerda Von Philipsborn

Horst Korioth

A combination of endothelin antagonists and beta-receptor blockers is described. The combination is suitable for controlling diseases.

Endothelin antagonist and beta receptor blocking agent as combined preparations

A combination of endothelin antagonists and RAS inhibitor is described. The combination is suitable for controlling diseases.

Endothelin antagonist and renin-angiotensin system inhibitor as a combined preparation

Diseases caused by obesity are treated with endothelin receptor antagonists. Diseases treated include those frequently associated with obesity such as hypertension, type 2 diabetes, hyperlipidemia, chronic kidney failure, arteriosclerosis and gout.

Method for combating obesity

Substituted N-phenylpiperidines I ##STR1## (R.sup.1 =H, NO.sub.2, CN, halogen, C.sub.1 -C.sub.4 -alkyl, CF.sub.3, OCF.sub.3, OH, CH.sub.2 OH, COOH, CHO, NH--CHO, NH.sub.2, CO--NH.sub.2, 5-tetrazinyl, R.sup.4 --O--, R.sup.4 --O--CH.sub.2 --, R.sup.4 O--CO--, R.sup.4 --CO--, R.sup.4 --NH--CO, R.sup.4 --CO--NH--, R.sup.4 --SO.sub.2 --NH--;

Substituted N-phenylpiperidines and drugs therefrom

Substituted anilides of the formula I ##STR1## (where R.sup.1 is C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4 -alkoxy, halogen, cyano, nitro, C.sub.2 -C.sub.4 -alkenyl, C.sub.2 -C.sub.4 -alkynyl;

Growing community of inventors

Mannheim, Germany

Michael Kirchengast